Genomic screen for epigenetically silenced tumor suppressor genes
AssigneeThe Johns Hopkins University School of Medicine
InventorDavid Sidransky
Life of this patent
Estimating the term…
Abstract
Methods of genomic screening to identify epigenetically silenced genes, including epigenetically silenced tumor suppressor genes are provided. Also provided are methods of detecting a cancer, for example, an esophageal squamous cell carcinoma or a head and neck squamous cell carcinoma, as are methods of treating a subject having such a cancer.
Claims140
A method of identifying at least one epigenetically silenced gene associated with a cancer, comprising:
- a) contacting an array of nucleotide sequences representative of a genome with nucleic acid molecules corresponding to RNA expressed in cancer cells contacted with at least one agent that reactivates expression of epigenetically silenced genes, under conditions suitable for selective hybridization of nucleic acid molecules to complementary nucleotide sequences of the array;
- and
- b) detecting increased hybridization of nucleic acid molecules of the cancer cells contacted with the at least one agent to a subpopulation of nucleotide sequences of the array,
- as compared to a level of hybridization, if any, of nucleic acid molecules corresponding to RNA expressed in the cancer cells to at least one nucleotide sequence of the subpopulation of nucleotide sequences, under said conditions,
- whereby said increased selective hybridization identifies reactivated expression of an epigenetically silenced gene,
- thereby identifying at least one epigenetically silenced gene associated with the cancer.
A method for identifying a cell that exhibits or is predisposed to exhibiting unregulated growth, comprising detecting, in a test cell, epigenetic silencing of at least one gene comprising a nucleic acid molecule as set forth in Table 2, Table 5, Table 6, or a combination thereof, thereby identifying the test cell as a cell that exhibits or is predisposed to exhibiting unregulated growth.
A method of reducing or inhibiting unregulated growth of a cell exhibiting epigenetic silenced transcription of at least one gene associated with a cancer, the method comprising restoring expression of a polypeptide encoded by the epigenetic silenced gene in the cell, thereby reducing or inhibiting unregulated growth of the cell.
A method for treating a cancer patient, wherein cancer cells in the patient exhibit epigenetic silenced expression of at least one gene, the method comprising restoring expression of the at least one epigenetic silenced gene in cancer cells in the subject, thereby treating the cancer patient.
A method for selecting a therapeutic strategy for treating a cancer patient, comprising:
- a) identifying at least one epigenetically silenced gene associated with the cancer by contacting an array of nucleotide sequences representative of a genome with nucleic acid molecules corresponding to RNA expressed in cancer cells contacted with at least one agent that reactivates expression of epigenetically silenced genes, under conditions suitable for selective hybridization of nucleic acid molecules to complementary nucleotide sequences of the array;
- and
- detecting increased hybridization of nucleic acid molecules of the cancer cells contacted with the at least one agent to a subpopulation of nucleotide sequences of the array, as compared to a level of hybridization, if any, of nucleic acid molecules corresponding to RNA expressed in the cancer cells to at least one nucleotide sequence of the subpopulation of nucleotide sequences, under said conditions, whereby said increased selective hybridization identifies reactivated expression of an epigenetically silenced gene, thereby identifying at least one epigenetically silenced gene associated with the cancer;
- and
- b) selecting an agent useful for restoring expression of the at least one epigenetically silenced gene in cancer cells of the patient, thereby selecting a therapeutic strategy for treating a cancer patient.
A method of treating a subject suffering from an esophageal squamous cell carcinoma (ESCC), wherein cells associated with the ESCC contain at least one epigenetic silenced gene, comprising administering an amount of an agent that restores expression of the at least one epigenetic silenced gene to the subject sufficient to restore expression of the epigenetic silenced gene in cells associated with the ESCC, thereby treating the subject.
An isolated oligonucleotide, comprising an oligonucleotide as set forth in any of SEQ ID NOS:1 to 127.
An amplification primer pair, comprising a forward primer and a reverse primer as set forth in SEQ ID NOS:1 to 127, wherein the amplification primer pair can amplify a portion of a nucleic acid molecule of Table 2.
Dependencies are inferred from the claim text.